Nifty
:
11247.55
Sensex
:
38067.93
25.15 (0.22%)
94.71 (0.25%)
Nifty
Sensex
:
:
11247.55
38067.93
25.15 (0.22%)
94.71 (0.25%)

Cadila Healthcare Ltd.

Pharmaceuticals & Drugs - Global

Rating :
65/99

BSE: 532321 | NSE: CADILAHC

NSE BSE
395.05
30-Sep-2020
  • Open
  • High
  • Low
  • Previous Close
  •  388.05
  •  406.50
  •  386.00
  •  387.80
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  7587170
  •  30282.91
  •  423.00
  •  202.00

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 39,675.14
  • 29.90
  • 1
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 46,709.54
  • 0.90%
  • 3.66

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 74.88%
  • 0.93%
  • 5.76%
  • FII
  • DII
  • Others
  • 4.56%
  • 8.71%
  • 5.16%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 11.90
  • 8.62
  • 6.04

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 10.59
  • 3.60
  • -0.34

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 4.91
  • -9.50
  • -12.49

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 25.53
  • 24.33
  • 20.41

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 5.52
  • 4.98
  • 3.80

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 16.93
  • 16.22
  • 14.24

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Jun 20
Jun 19
Var%
Mar 20
Mar 19
Var%
Dec 19
Dec 18
Var%
Sep 19
Sep 18
Var%
Net Sales
3,639.90
3,496.30
4.11%
3,752.10
3,732.80
0.52%
3,638.10
3,577.90
1.68%
3,366.60
2,961.20
13.69%
Expenses
2,824.50
2,864.30
-1.39%
2,960.90
2,932.40
0.97%
2,944.90
2,738.00
7.56%
2,741.00
2,273.40
20.57%
EBITDA
815.40
632.00
29.02%
791.20
800.40
-1.15%
693.20
839.90
-17.47%
625.60
687.80
-9.04%
EBIDTM
22.40%
18.08%
14.01%
21.44%
19.05%
23.47%
18.58%
23.23%
Other Income
22.50
22.60
-0.44%
44.30
38.40
15.36%
20.10
31.00
-35.16%
26.90
30.40
-11.51%
Interest
67.70
89.10
-24.02%
82.50
77.30
6.73%
80.50
45.50
76.92%
89.70
35.70
151.26%
Depreciation
176.80
171.60
3.03%
178.50
155.60
14.72%
174.10
153.70
13.27%
172.30
147.50
16.81%
PBT
593.40
393.90
50.65%
522.00
605.90
-13.85%
457.10
671.70
-31.95%
122.40
535.00
-77.12%
Tax
123.50
79.10
56.13%
108.50
126.70
-14.36%
92.70
158.60
-41.55%
39.50
124.70
-68.32%
PAT
469.90
314.80
49.27%
413.50
479.20
-13.71%
364.40
513.10
-28.98%
82.90
410.30
-79.80%
PATM
12.91%
9.00%
7.11%
12.84%
10.02%
14.34%
2.46%
13.86%
EPS
4.59
3.08
49.03%
4.04
4.68
-13.68%
3.56
5.01
-28.94%
0.81
4.01
-79.80%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Net Sales
14,396.70
14,253.10
13,165.60
11,954.50
9,376.50
9,426.80
8,651.30
7,224.00
6,357.70
5,263.30
4,630.60
Net Sales Growth
4.56%
8.26%
10.13%
27.49%
-0.53%
8.96%
19.76%
13.63%
20.79%
13.66%
 
Cost Of Goods Sold
8,295.20
4,243.30
4,141.30
3,656.90
3,065.00
2,673.20
2,814.10
2,412.60
2,036.80
1,464.10
1,286.20
Gross Profit
6,101.50
10,009.80
9,024.30
8,297.60
6,311.50
6,753.60
5,837.20
4,811.40
4,320.90
3,799.20
3,344.40
GP Margin
42.38%
70.23%
68.54%
69.41%
67.31%
71.64%
67.47%
66.60%
67.96%
72.18%
72.22%
Total Expenditure
11,471.30
11,472.90
10,197.60
9,125.90
7,475.00
7,097.30
6,897.40
6,031.20
5,234.00
4,181.50
3,614.10
Power & Fuel Cost
-
268.80
247.20
226.30
174.50
168.80
145.40
129.70
124.40
93.40
78.90
% Of Sales
-
1.89%
1.88%
1.89%
1.86%
1.79%
1.68%
1.80%
1.96%
1.77%
1.70%
Employee Cost
-
2,389.80
2,099.40
1,825.20
1,485.20
1,261.60
1,096.50
974.00
818.40
679.90
584.00
% Of Sales
-
16.77%
15.95%
15.27%
15.84%
13.38%
12.67%
13.48%
12.87%
12.92%
12.61%
Manufacturing Exp.
-
1,468.00
1,334.70
1,211.40
955.30
1,019.60
1,136.90
936.50
897.30
718.90
553.40
% Of Sales
-
10.30%
10.14%
10.13%
10.19%
10.82%
13.14%
12.96%
14.11%
13.66%
11.95%
General & Admin Exp.
-
909.20
589.10
504.60
466.00
432.70
326.80
365.70
342.20
271.90
234.90
% Of Sales
-
6.38%
4.47%
4.22%
4.97%
4.59%
3.78%
5.06%
5.38%
5.17%
5.07%
Selling & Distn. Exp.
-
1,209.50
1,035.40
1,014.50
826.40
979.60
960.30
902.40
857.50
767.40
710.70
% Of Sales
-
8.49%
7.86%
8.49%
8.81%
10.39%
11.10%
12.49%
13.49%
14.58%
15.35%
Miscellaneous Exp.
-
984.30
750.50
687.00
502.60
561.80
417.40
310.30
157.40
185.90
710.70
% Of Sales
-
6.91%
5.70%
5.75%
5.36%
5.96%
4.82%
4.30%
2.48%
3.53%
3.58%
EBITDA
2,925.40
2,780.20
2,968.00
2,828.60
1,901.50
2,329.50
1,753.90
1,192.80
1,123.70
1,081.80
1,016.50
EBITDA Margin
20.32%
19.51%
22.54%
23.66%
20.28%
24.71%
20.27%
16.51%
17.67%
20.55%
21.95%
Other Income
113.80
117.10
206.20
113.30
147.10
116.60
57.20
58.00
38.40
53.00
22.80
Interest
320.40
341.80
193.50
91.10
63.10
52.80
67.90
90.20
168.70
182.70
69.90
Depreciation
701.70
696.50
598.60
538.80
373.30
292.10
287.30
201.20
184.70
157.90
126.90
PBT
1,694.90
1,859.00
2,382.10
2,312.00
1,612.20
2,101.20
1,455.90
959.40
808.70
794.20
842.50
Tax
364.20
319.80
530.30
564.40
128.90
177.40
259.40
106.00
118.80
113.00
106.40
Tax Rate
21.49%
21.39%
22.26%
24.41%
8.00%
8.45%
17.95%
11.25%
14.69%
14.23%
12.63%
PAT
1,330.70
1,147.80
1,801.90
1,713.00
1,453.90
1,890.90
1,148.50
803.60
653.50
652.60
711.00
PAT before Minority Interest
1,313.80
1,175.60
1,851.80
1,747.60
1,483.00
1,921.30
1,186.10
836.20
689.90
681.20
736.10
Minority Interest
-16.90
-27.80
-49.90
-34.60
-29.10
-30.40
-37.60
-32.60
-36.40
-28.60
-25.10
PAT Margin
9.24%
8.05%
13.69%
14.33%
15.51%
20.06%
13.28%
11.12%
10.28%
12.40%
15.35%
PAT Growth
-22.52%
-36.30%
5.19%
17.82%
-23.11%
64.64%
42.92%
22.97%
0.14%
-8.21%
 
EPS
13.00
11.21
17.60
16.73
14.20
18.47
11.22
7.85
6.38
6.37
6.95

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Shareholder's Funds
10,375.70
10,386.30
8,744.50
6,960.00
5,699.20
4,251.60
3,439.00
2,944.50
2,585.90
2,171.50
Share Capital
102.40
102.40
102.40
102.40
102.40
102.40
102.40
102.40
102.40
102.40
Total Reserves
10,273.30
10,283.90
8,642.10
6,857.60
5,596.80
4,149.20
3,336.60
2,842.10
2,483.50
2,069.10
Non-Current Liabilities
2,853.90
3,491.10
2,122.20
1,903.30
736.10
1,341.50
1,589.20
1,640.00
1,555.10
956.30
Secured Loans
1,953.60
1,578.00
200.60
319.60
393.80
664.00
851.40
917.20
901.90
670.90
Unsecured Loans
1,261.00
2,371.70
2,354.50
2,148.80
502.60
486.40
510.80
508.80
420.40
92.00
Long Term Provisions
235.20
184.10
155.90
151.20
120.70
90.40
76.10
66.50
75.60
61.90
Current Liabilities
8,269.40
7,342.50
6,083.00
5,305.80
3,461.00
3,285.10
2,814.00
2,670.40
2,191.60
1,415.90
Trade Payables
2,031.00
1,922.60
1,888.40
1,547.90
1,308.10
1,090.90
910.80
656.80
545.50
570.60
Other Current Liabilities
2,139.60
2,033.60
1,484.90
1,212.10
860.70
628.20
708.10
509.20
730.90
367.30
Short Term Borrowings
3,826.50
3,196.90
2,557.50
2,476.90
1,210.90
1,183.50
902.40
1,257.10
687.10
259.80
Short Term Provisions
272.30
189.40
152.20
68.90
81.30
382.50
292.70
247.30
228.10
218.20
Total Liabilities
22,833.70
22,512.80
17,140.70
14,325.20
10,032.10
9,047.10
7,986.50
7,374.20
6,423.00
4,610.60
Net Block
12,230.50
12,163.70
6,482.60
5,755.10
3,747.90
3,352.20
3,123.80
3,025.60
2,857.10
1,832.60
Gross Block
16,781.50
15,702.30
9,349.10
8,102.90
5,767.30
5,138.50
4,664.00
4,376.20
3,990.90
2,801.70
Accumulated Depreciation
4,551.00
3,538.60
2,866.50
2,345.80
2,016.80
1,786.30
1,540.20
1,350.60
1,096.00
929.90
Non Current Assets
14,118.30
14,014.70
8,911.00
8,302.90
5,751.70
4,820.40
4,548.60
4,182.50
3,610.00
2,485.30
Capital Work in Progress
741.50
837.20
1,527.20
1,543.30
950.80
797.90
891.50
735.60
483.90
431.00
Non Current Investment
552.20
443.60
470.90
385.70
217.10
33.20
22.20
21.20
21.20
20.70
Long Term Loans & Adv.
332.00
410.40
300.00
384.70
661.20
637.10
511.10
400.10
247.80
201.00
Other Non Current Assets
262.10
159.80
130.30
234.10
174.70
0.00
0.00
0.00
0.00
0.00
Current Assets
8,715.40
8,498.10
8,229.70
6,022.30
4,280.40
4,226.70
3,437.90
3,191.70
2,813.00
2,125.30
Current Investments
212.80
229.90
274.80
49.10
199.10
121.20
64.40
93.30
3.00
0.00
Inventories
2,789.00
2,688.00
2,385.30
1,803.70
1,337.10
1,535.70
1,367.50
1,213.60
1,090.50
811.90
Sundry Debtors
3,663.20
3,950.80
3,206.30
2,277.50
1,746.60
1,588.40
1,133.70
955.10
920.90
765.20
Cash & Bank
964.90
649.30
1,314.90
1,543.50
638.70
669.90
548.80
583.80
466.60
295.20
Other Current Assets
1,085.50
395.60
520.70
80.00
358.90
311.50
323.50
345.90
332.00
253.00
Short Term Loans & Adv.
643.90
584.50
527.70
268.50
234.80
240.80
254.90
279.00
274.60
206.20
Net Current Assets
446.00
1,155.60
2,146.70
716.50
819.40
941.60
623.90
521.30
621.40
709.40
Total Assets
22,833.70
22,512.80
17,140.70
14,325.20
10,032.10
9,047.10
7,986.50
7,374.20
6,423.00
4,610.60

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Cash From Operating Activity
2,505.40
2,882.30
919.30
1,311.70
1,893.50
993.60
902.80
603.40
511.10
682.60
PBT
1,495.40
2,382.10
2,312.00
1,611.90
2,098.70
1,445.50
942.20
808.70
794.20
842.50
Adjustment
1,182.70
664.30
624.30
333.70
249.80
344.50
269.00
315.90
320.90
208.40
Changes in Working Capital
129.40
637.80
-1,383.90
-411.20
271.70
-377.00
-20.10
-201.60
-421.70
-175.30
Cash after chg. in Working capital
2,807.50
3,684.20
1,552.40
1,534.40
2,620.20
1,413.00
1,191.10
923.00
693.40
875.60
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-302.50
-675.40
-602.30
-237.60
-646.00
-386.90
-172.80
-272.00
-143.50
-152.50
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.40
-126.50
-30.80
14.90
-80.70
-32.50
0.00
0.00
0.00
0.00
Cash From Investing Activity
-1,012.30
-5,738.70
-973.70
-2,871.90
-863.50
-464.70
-438.00
-682.30
-1,199.50
-466.00
Net Fixed Assets
-1,372.00
-569.90
-600.20
-557.40
-531.50
-271.50
-239.50
-646.90
-361.70
-266.60
Net Investments
-1,679.20
-1,106.80
305.60
-1,606.20
-108.40
-651.40
-277.80
-67.70
-513.40
-99.90
Others
2,038.90
-4,062.00
-679.10
-708.30
-223.60
458.20
79.30
32.30
-324.40
-99.50
Cash from Financing Activity
-1,094.20
1,884.60
51.50
2,315.80
-934.80
-351.10
-528.70
285.80
859.80
-172.10
Net Cash Inflow / Outflow
398.90
-971.80
-2.90
755.60
95.20
177.80
-63.90
206.90
171.40
44.50
Opening Cash & Equivalents
778.80
1,589.70
1,592.60
837.00
737.90
612.60
676.50
469.60
295.20
250.70
Closing Cash & Equivalent
1,177.70
879.20
1,589.70
1,592.60
837.00
790.40
612.60
676.50
466.60
295.20

Financial Ratios

Consolidated /

Standalone
Description
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Book Value (Rs.)
101.33
101.43
85.40
67.97
55.66
41.52
33.58
28.75
25.25
21.21
ROA
5.18%
9.34%
11.11%
12.18%
20.14%
13.93%
10.89%
10.00%
12.35%
17.62%
ROE
11.32%
19.36%
22.26%
23.43%
38.62%
30.85%
26.20%
24.95%
28.64%
38.85%
ROCE
10.02%
15.88%
18.26%
16.50%
28.60%
23.21%
17.20%
18.21%
24.01%
30.56%
Fixed Asset Turnover
0.88
1.05
1.38
1.38
1.76
1.80
1.63
1.55
1.58
1.75
Receivable days
97.49
99.21
83.37
76.72
63.29
56.38
51.71
52.78
57.47
47.97
Inventory Days
70.13
70.33
63.69
59.88
54.52
60.13
63.89
64.82
64.85
60.83
Payable days
68.68
72.33
71.11
74.18
67.53
55.78
50.51
43.54
49.87
64.40
Cash Conversion Cycle
98.94
97.21
75.95
62.42
50.28
60.73
65.09
74.05
72.45
44.40
Total Debt/Equity
0.77
0.76
0.62
0.75
0.43
0.62
0.79
0.99
0.89
0.50
Interest Cover
5.38
13.31
26.38
26.55
40.75
22.29
11.45
5.79
5.35
13.05

Annual Reports:

FY 2020
FY 2019
FY 2018
FY 2017
FY 2016
FY 2015
FY 2014
FY 2013
FY 2012
FY 2011

News Update:


  • Zydus Cadila gets approval to market Dimethyl Fumarate Delayed Release Capsules
    25th Sep 2020, 10:58 AM

    The group now has 303 approvals and has so far filed over 390 ANDAs since the commencement

    Read More
  • Zydus Cadila gets approval from USFDA to market Palbociclib Capsules
    24th Sep 2020, 10:56 AM

    The group now has 302 approvals and has so far filed over 390 ANDAs since the commencement of the filing process in FY 2003-04

    Read More
  • CRISIL reaffirms rating of Cadila Healthcare’s Commercial Paper
    22nd Sep 2020, 16:50 PM

    CRISIL has, after due deliberations, reaffirmed its A1+ on the Rs 1,300 crore Commercial Paper

    Read More
  • Zydus Cadila gets final approval from USFDA to market Potassium Chloride Extended-Release Tablets
    18th Sep 2020, 11:15 AM

    The group now has 301 approvals and has so far filed over 390 ANDAs since the commencement of the filing process in FY 2003-04

    Read More
  • Zydus Cadila gets nod from USFDA for Doxorubicin Hydrochloride Liposome Injection
    11th Sep 2020, 14:09 PM

    This is the group’s first approval for a complex injectable which has been developed in-house

    Read More
  • Zydus Cadila gets tentative approval from USFDA for Empagliflozin, Linagliptin Tablets
    9th Sep 2020, 13:12 PM

    Empagliflozin and Linagliptin are oral diabetes medicines that help control blood sugar levels

    Read More
  • Zydus Cadila gets final approval from USFDA for Midodrine Hydrochloride Tablets
    3rd Sep 2020, 12:11 PM

    The drug is used for certain patients who have symptoms of low blood pressure when standing

    Read More
  • Zydus Cadila gets approval from USFDA to market Cisatracurium Besylate Injection
    2nd Sep 2020, 10:59 AM

    The group now has 297 approvals and has so far filed over 390 ANDAs

    Read More
  • Zydus Cadila gets final nod from USFDA for Sevelamer Carbonate Tablets
    13th Aug 2020, 14:10 PM

    The drug will be manufactured at the group’s formulation manufacturing facility at SEZ, Ahmedabad

    Read More
  • Zydus Cadila launches Remdesivir for treatment of COVID-19 in India
    13th Aug 2020, 09:32 AM

    Priced at Rs 2800 for a 100 mg lyophilized injection, Remdac is the most economical Remdesivir brand in India

    Read More
  • Cadila Healthcare reports 50% rise in Q1 consolidated net profit
    6th Aug 2020, 11:18 AM

    Total income of the company increased by 4.08% at Rs 3662.40 crore for Q1FY21

    Read More
  • Cadila Healthcare - Quarterly Results
    5th Aug 2020, 11:46 AM

    Read More
  • Zydus Cadila gets USFDA’s tentative nod for Carbidopa, Levodopa extended-release capsules
    3rd Aug 2020, 08:53 AM

    This medication is used to treat the symptoms of Parkinson’s disease or Parkinson-like conditions

    Read More
  • Zydus Cadila gets USFDA’s nod to initiate clinical trials of Desidustat in CIA
    23rd Jul 2020, 09:57 AM

    Desidustat is expected to increase the red blood cell count and restore the erythropoietin levels to the normal levels in the cancer patients with CIA

    Read More
  • Zydus Cadila to complete clinical trials of COVID-19 vaccine in seven months
    20th Jul 2020, 10:34 AM

    The company had started clinical trials of its COVID-19 vaccine candidate with the first human dosing

    Read More
  • Zydus Cadila gets USFDA's approval for Butalbital, Acetaminophen, Caffeine Tablets
    18th Jul 2020, 11:52 AM

    This combination of medication is used to treat symptom complex of tension (or muscle contraction) headache

    Read More
  • Zydus receives approval to conduct clinical trials in Mexico to treat coronavirus
    17th Jul 2020, 09:50 AM

    The company has received approval to conduct clinical trials with its biological therapy, Pegylated Interferon alpha-2b, ‘PegiHepTM’ to treat novel coronavirus

    Read More
  • Zydus Cadila gets sANDA approval from USFDA for manufacturing of Doxycycline Injection
    16th Jul 2020, 12:25 PM

    The group now has 293 approvals and has so far filed over 390 ANDAs since the commencement of the filing process in FY 2003-04

    Read More
  • Zydus Cadila gets USFDA's final approval for Betamethasone Dipropionate Ointment
    15th Jul 2020, 12:46 PM

    Betamethasone Dipropionate Ointment is used to treat a variety of skin conditions

    Read More
  • Zydus Cadila commences first human dosing of plasmid DNA vaccine ‘ZyCoV-D’
    15th Jul 2020, 09:52 AM

    The human dosing of the vaccine marks a key milestone since the launching of the accelerated vaccine development programme for COVID-19 in February 2020

    Read More
  • Zydus Cadila gets approval from COFEPRIS to study Desidustat in management of COVID-19
    6th Jul 2020, 09:46 AM

    Clinical and regulatory development of Desidustat in COVID-19 is being executed in Mexico by Avant Santé Research Center S.A. de C.V., a leading CRO

    Read More
  • Zydus Cadila’s vaccine for COVID-19 completes preclinical phase, gets nod to initiate human clinical trials
    3rd Jul 2020, 09:54 AM

    The company has already manufactured clinical GMP batches of the vaccine candidate and plans to initiate the clinical trials in July 2020 across multiple sites in India

    Read More
  • Zydus Cadila gets USFDA's final approval for Meclizine Hydrochloride Tablets
    24th Jun 2020, 13:52 PM

    Meclizine is an antihistamine that is used to prevent and treat nausea, vomiting, and dizziness caused by motion sickness

    Read More
  • Cadila Healthcare reports 15% fall in Q4 consolidated net profit
    22nd Jun 2020, 15:23 PM

    Total income of the company increased by 0.67% at Rs 3796.40 crore for Q4FY20

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.